There is a six-fold prevalence of schizophrenia in people with HIV than that of the population without the virus, according to the results of a Vancouver, BC, Canada-based study. The study, presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA, this week, found a distinct association between the mental disorder and HIV — a relationship sparsely analyzed before.
Researchers from the British Columbia Centre for Excellence in HIV/AIDS in Vancouver, performed a population-based retrospective cohort study that estimated schizophrenia prevalence and mortality outcomes in the people living with HIV, and a randomly selected 10% sample of individual in British Columbia, from 1998 to 2013.
“We found that with this group — because they had the highest mortality — having access to psychiatric care or psychiatric meds, as well as accessing a psychiatrist, was associated with reduced odds of mortality,”
Led by research coordinator Kalysha Closson, MSc, the team assessed schizophrenia prevalence with physician and hospital-based administrative data, as well as International Classification of Disease 9/10 codes.
The survival time by HIV-status was accessed by a Kaplan-Meier plot, and age and sex-adjusted mortality rates were calculated with the 2016 Canada population used as reference. Researchers examined the association between HIV and all-cause mortality among patients with schizophrenia using logistic regression.
Results showed that, of the 515,913 British Columbia residents from 1998 to 2013 observed in the study, 13,412 (2.6%) were people living with HIV. Schizophrenia was diagnosed in 6.3% of that population — a significant jump from the diagnosis rate in the non-HIV population (1.1%; P < 0.001).
Among those with both HIV and schizophrenia, the population was mostly male (75%), living in an urban setting (91%), had a history of injection drug use (75%), and was at least once on anti-psychotic medication (49%; P <0.001). The population of patients with schizophrenia, but not HIV, reported lesser rates for injection drug use (20%) and antipsychotic medication (39%).
To read the complete article by Kevin Kunzmann @Kevin_MDMag, visit MD Mag, here.